Back to News
Market Impact: 0.2
Raymond James Initiates Coverage of Nektar Therapeutics with Market Perform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 9, 2026, Raymond James initiated coverage of Nektar Therapeutics with a Market Perform recommendation, while BTIG reiterated its Buy rating. The article says the stock had closed at $40.80 before these actions; it provides no subsequent share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
NKTR0.10
More News
- Trading expert sets date when Micron (MU) stock will crash to $400
- Merck’s remigromig meets non-inferiority goal in DME trial
- Bank of America is bullish on these top stocks ahead of earnings
- Strong Earnings Keep US Stocks in Favor
- JPMorgan makes bullish call in fixed income space, suggests it's a once in a generation opportunity
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off